瑞典2型糖尿病并发症的经济负担:住院医疗与工作缺勤成本分析
该研究基于瑞典1997-2016年全国登记数据,纳入392,200例2型糖尿病患者及5:1匹配对照,分析2016年住院和门诊医疗成本及工作缺勤成本。结果显示,糖尿病患者并发症相关住院使用率和成本显著高于对照(€919 vs €232/人),工作缺勤成本中并发症相关部分为€1317/人。
要点
- 2型糖尿病并发症相关住院医疗成本显著高于匹配对照(€919 vs €232/人)。
- 并发症相关工作缺勤成本达€1317/人,占总缺勤成本的25%。
- 大血管并发症(心绞痛、心衰、卒中)和微血管并发症(眼病、肾病、神经病变)是成本主要驱动因素。
核心结论
- 2型糖尿病并发症的经济负担显著,工作缺勤成本高于住院医疗成本,需从社会视角考虑治疗后果。
研究设计与样本
- 基于瑞典全国回顾性观察数据库,交叉链接1997-2016年个人水平数据,纳入392,200例2型糖尿病患者及5:1匹配对照,估算2016年成本。
主要发现
- 2016年糖尿病患者发生≥1次住院接触的比例为26% vs 对照12%,门诊就诊86,104 vs 24,608次/10万人,住院9894 vs 2546次/10万人(均p<0.001)。
- 并发症相关住院医疗总成本为€919 vs €232/人(p<0.001),其中74.7%直接归因于糖尿病(€687/人)。
- 并发症相关工作缺勤成本为€1317/人,占总缺勤成本的25%;工作年龄早亡额外成本€579/人,风险因素治疗药物成本€418/人。
- 成本主要驱动因素为大血管并发症(心绞痛、心衰、卒中)和微血管并发症(眼病包括视网膜病变、肾病、神经病变)。
关键数值与推荐
- 糖尿病患者并发症相关住院使用率:26% vs 12%(对照),p<0.001。
- 门诊就诊率:86,104 vs 24,608次/10万人;住院率:9894 vs 2546次/10万人(均p<0.001)。
- 并发症相关住院成本:€919 vs €232/人(p<0.001),其中€687/人直接归因于糖尿病(74.7%)。
- 并发症相关工作缺勤成本:€1317/人,占总缺勤成本的25%。
临床怎么用
- 临床应重视2型糖尿病并发症的预防和管理,以降低住院医疗和工作缺勤的社会经济负担。
- 大血管和微血管并发症均为成本驱动因素,需综合管理心绞痛、心衰、卒中、视网膜病变、肾病和神经病变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The risk of complications and medical consequences of type 2 diabetes are well known. Hospital costs have been identified as a key driver of total costs in studies of the economic burden of type 2 diabetes. Less evidence has been generated on the impact of individual diabetic complications on the overall societal burden. The objective of this study was to analyse costs of hospital-based healthcare (inpatient and outpatient care) and work absence related to individual macrovascular and microvascular complications of type 2 diabetes in Sweden in 2016. METHODS: Data for 2016 were retrieved from a Swedish national retrospective observational database cross-linking individual-level data for 1997-2016. The database contained information from population-based health, social insurance and socioeconomic registers for 392,200 people with type 2 diabetes and matched control participants (5:1). Presence of type 2 diabetes and of diabetes complications were derived using all years, 1997-2016. Costs of hospital-based care and of absence from work due to diabetes complications were estimated for the year 2016. Regression analysis was used for comparison with control participants to attribute absence from work to individual complications, and to account for joint presence of complications. RESULTS: Use of hospital care for complications was higher in type 2 diabetes compared with control participants in 2016: 26% vs 12% had ≥1 hospital contact; there were 86,104 vs 24,608 outpatient visits per 100,000 people; and there were 9894 vs 2546 inpatient admissions per 100,000 people (all p < 0.001). The corresponding total costs of hospital-based care for complications were €919 vs €232 per person (p < 0.001), and 74.7% of costs were then directly attributed to diabetes (€687 per person). Regression analyses distributed the costs of days absent from work across diabetes complications per se, basic type 2 diabetes effect and unattributed causes. Diabetes complications amounted to €1317 per person in 2016, accounting for possible complex interactions (25% of total costs of days absent). Key drivers of costs were the macrovascular complications angina pectoris, heart failure and stroke; and the microvascular complications eye diseases, including retinopathy, kidney disease and neuropathy. Early mortality in working ages cost an additional €579 per person and medications used in risk-factor treatment amounted to €418 per person. CONCLUSIONS/INTERPRETATION: The economic burden of complications in type 2 diabetes is substantial. Costs of absence from work in this study were found to be greater than of hospital-based care, highlighting the need for considering treatment consequences in a societal perspective in research and policy. Graphical abstract.
引用
- Andersson E, Persson S, Hallén N, et al. Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden. Diabetologia. 2020. PMID: 32968866. doi:10.1007/s00125-020-05277-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。